Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis
A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is the first-line treatment for Class III, IV, and V lupus nephritis. Among the 139 single nucleotide polymorphisms (SNPs) associated with cyclophosphamide, four SNPs, namely rs4244285, rs4802101, rs72545...
Saved in:
| Main Authors: | Yen Yen Ari Indrawijaya, Laniyati Hamijoyo, Aluicia Anita Artarini, Maria Immaculata Iwo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2023-11-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India
by: V Jayaprakash, et al.
Published: (2020-01-01) -
Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review
by: Siva Hamdani, et al.
Published: (2025-06-01) -
CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study
by: Heba M. Elmaraghy, et al.
Published: (2025-06-01) -
Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center
by: Han Y, et al.
Published: (2025-07-01) -
Splenectomy following rituximab and cyclophosphamide for severe autoimmune hemolytic anemia in pregnancy
by: Tao Wang, et al.
Published: (2025-12-01)